Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9339087 | 0.90 | PARP1 (0.47) | PARP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30666151 | 0.87 | PARP1 (0.51) | PARP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29169651 | 0.86 | NAPRT (0.55) | KDM4EALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL62707 | 0.86 | PARP1 (0.50) | PARP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1937751 | 0.85 | PARP1 (0.53) | PARP1KDM4EALDH1A1HPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL30786354 | 0.84 | PARP1 (0.49) | PARP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL2497122 | 0.84 | KDM4E (0.56) | PARP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5196284 | 0.81 | PARP1 (0.53) | PARP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL497429 | 0.81 | PARP1 (0.53) | PARP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL4601500 | 0.81 | KDM4E (0.54) | PARP1KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4472948-A2 | NICOTINATE AND NICOTINAMIDE RIBOSIDE-BASED COMPOUNDS AND DERIVATIVES THEREOF | New Frontier Bio, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| EP-3010886-B1 | RETINOID DERIVATIVES AND PROCESS FOR THEIR PREPARATION | SELEGO AB (SE) | 2018-02-28 | — | — | EP | disclosed |
| US-9549884-B2 | Retinoid derivatives and process for their preparation | SELEGO AB (SE) | 2017-01-24 | — | — | US | disclosed |
| US-20160136076-A1 | RETINOID DERIVATIVES AND PROCESS FOR THEIR PREPARATION | SELEGO AB (SE) | 2016-05-19 | — | — | US | disclosed |
| EP-3010886-A1 | RETINOID DERIVATIVES AND PROCESS FOR THEIR PREPARATION | Selego AB (SE) | 2016-04-27 | — | — | EP | disclosed |
| WO-2014204390-A1 | RETINOID DERIVATIVES AND PROCESS FOR THEIR PREPARATION | SELEGO AB (SE) | 2014-12-24 | — | — | WO | disclosed |
| US-8138209-B2 | Substituted picolinamides as MAO-B inhibitors useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| WO-2007008963-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20070015734-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-18 | — | — | US | disclosed |
| US-5360808-A | Cardiovascular disorders, antispasmodic agents, hypotensive disorders, brains, anticonvulsants and antiepileptics | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-11-01 | — | — | US | disclosed |
| EP-0556738-A1 | Pyridinylcarbonylaminoalkyl-dihydro-oxo-pyridines, their production and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015734-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | PARP1 2110/4885KDM4E 610/4885ALDH1A1 353/4885 |
| US-20160136076-A1 | RETINOID DERIVATIVES AND PROCESS FOR THEIR PREPARATION | RARB, RARA, RARG | PARP1 3389/4885KDM4E 3174/4885ALDH1A1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.